Objective: Postnatal resident endothelium of blood vessels has been proposed to represent terminally differentiated tissue that does not replicate. We previously isolated endothelial colony-forming cells (ECFCs) from human umbilical cord blood (CB) and term placenta by using colony-forming assays and immunocytochemistry. We showed that ECFCs are highly proliferative and form functioning vessels in vivo, the defining characteristics of a true endothelial progenitor cell. This exploratory investigation was conducted to determine whether the endothelium of healthy adult blood vessels contained resident ECFCs.
The original paradigm of blood vessel growth and repair emanating from the migration, proliferation, and differentiation of luminal endothelial cells was permutated with the sentinel description of a circulating endothelial progenitor cell (EPC). 1 In original report by Asahara et al, 1 cluster of differentiation (CD) 34 þ EPCs isolated from adult human peripheral blood formed spindle-shaped colonies when plated on fibronectin and expressed cell surface proteins characteristic of endothelial cells. Furthermore, these EPCs localized to areas of neovascularization when injected into animal models of hind limb ischemia. Subsequent studies proposed that EPCs originate in the bone marrow, migrate into the peripheral circulation, and home to areas of ischemia or vascular injury to differentiate into endothelial cells. [2] [3] [4] These reports brought forth a new concept of postnatal vasculogenesis that is mediated by circulating bone marrow-derived progenitor cells. 1, [5] [6] [7] Two types of EPCs have subsequently been isolated from adult peripheral blood. These two subtypes of EPCs are distinguished by the chronologic appearance of cell colonies in culture and by their in vitro and in vivo functional characteristics. "Early" EPCs appear in culture at 4 to 7 days as spindle-shaped colonies and have a short, nonproliferative life span of 3 to 4 weeks. "Late" EPCs, or endothelial colony-forming cells (ECFCs), have been isolated and characterized from umbilical cord blood (CB) by using clonal plating techniques. 8 
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ECFCs are organized in a hierarchy of progenitor stages
From the Health Center for Aortic Disease, a Department of Cellular and Integra-that vary in proliferative potential similar to that found in hematopoietic stem cells and express the endothelial surface antigens CD144 (vascular endothelial cadherin), CD31 (platelet endothelial cell adhesion molecule), and CD146 (melanoma cell adhesion molecule). 8, 9 When transplanted into nonobese diabetic (NOD)/severe combined immune deficiency (SCID) mice, ECFCs formed intact vessels containing murine red blood cells, thus demonstrating characteristics of a true EPC; that is, the ability to proliferate and differentiate into functioning tissue of the intended lineage. 9 Resident progenitor cells have been identified in liver, adipose, and skeletal muscle. [10] [11] [12] [13] Satellite cells, a muscle progenitor cell, reside dormant beneath the basal lamina of mature skeletal muscle fibers and possess the capacity to proliferate and differentiate into myofibers. 13, 14 Adipose stromal cells have been isolated from the stromal vascular fraction of adult adipose tissue with the capacity to differentiate into hepatocytes, skeletal muscle, cardiomyocytes, and neurons. 15, 16 Based on this background and the descriptive analyses of ECFCs, we hypothesized that adult endothelium would be a niche for resident progenitor cells.
METHODS
Collection of great saphenous vein endothelium and umbilical CB mononuclear cells. All tissue samples were collected according to the approved protocol of the Indiana University School of Medicine. The umbilical cord vein from term placentas (n ¼ 5) from caesarean deliveries was infused with 100 U of heparin (Baxter, Deerfield, Ill), and CB (50-80 mL) was collected in citrate phosphate dextrose solution. The CB was underlayed with 20 mL of Ficoll-Paque Plus (GE Health Care, Piscataway, NJ) and centrifuged at 1500 rpm for 30 minutes. The mononuclear cell fraction was collected, washed twice with phosphate-buffered saline (PBS) and 2% fetal bovine serum (FBS), and resuspended in 4 mL of endothelial growth medium (EGM)-2 medium (Cambrex, Walkersville, Md) supplemented with 10% FBS, 2% penicillin/streptomycin (Gibco, Invitrogen, Grand Island, NY), and 0.25 mg/mL amphotericin B (Invitrogen).
Great saphenous veins (GSVs) from vein stripping procedures for venous insufficiency (n ¼ 9) were collected, inverted, and divided longitudinally, and the endothelial surface was washed twice with PBS (Invitrogen) to remove residual blood. A 24-cm Cell Scraper (TPP, Trasadingen, Switzerland) was gently passed once along the intimal surface of the GSV, and cells collected on the blade were washed into 10 mL of PBS. The cell suspension was centrifuged at 1620 rpm for 10 minutes and resuspended in PBS supplemented with 10% FBS. Viable cells were counted using trypan blue (Invitrogen, Carlsbad, Calif) exclusion and a hemocytometer. Cells were then centrifuged for 10 minutes at 1620 rpm and resuspended in 3 mL of complete EGM-2 medium. growth kinetic curves, PD times (PDTs), and cumulative PD levels (CPDLs). The number of PDs occurring between passages was calculated according to the equation: PD ¼ log 2 (C H /C S ), where C H is the number of viable cells at harvest and C S is the number of cells seeded. The sum of all previous PDs determined the CPDL at each passage. The PDT was derived using the time interval between cell seeding and harvest divided by the number of PDs for that passage.
Single-cell assays. Single-cell assays were performed as previously described with minor modifications. 10 ECFCs (passage 2) were first labeled with CD144-PE. The FACSVantage Sorter (BD Biosciences) was used to place a single CD144 þ cell per well of a 96-well tissue culture plate precoated with type 1 collagen containing 200 mL of complete EGM-2 culture medium. Cells were incubated in a humidified chamber at 37 C with 5% CO 2 , and the medium was changed every 4 days with complete EGM-2. To determine the number of single dividing cells, wells were examined at day 14 of culture with a light microscope (original magnification Â40), and wells with two or more ECFCs were counted as positive for at least one cell division. To stratify colonies by proliferative capacity, cells were counted by light microscopy if there were #50 cells per well. Wells containing >50 cells per well were trypsinized and counted using a hemocytometer. Progeny were then stratified by the percentage of single cells that gave rise to endothelial clusters (<50 cells), low proliferative potential colonies (50-500 cells), and high proliferative potential colonies (HPP, >500 cells).
Embryonic stem cell antigen expression. To assess expression of the embryonic pluripotency markers, octamer-binding transcription factor 4 (Oct-4), Nanog, stage specific embryonic antigen-3 (SSEA-3), and SSEA-4, GSV and CB ECFCs were fixed in 4% paraformaldehyde supplemented with 125 mmol/L N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES)
for 20 minutes at 4 C, washed twice with PBS, and permeabilized with 0.1% Triton X-100 for 10 minutes at 4 C.
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GSV and CB ECFCs were blocked 1% bovine serum albumin and 1% casein for 1 hour and then stained with one of four different primary antibodies at a concentration of 2 to 4 mg/mL for 1 hour at room temperature: mouse mono- In vivo vasculogenesis assay. All mouse protocols and animal care were performed according to institutional standards and have been approved by IACUC. Cellularized gel implants were cast with minor modifications. 11 Cultured ECFCs (1 Â 10 6 cells/mL) were suspended in a solution consisting of 100 ng/mL human fibronectin (Chemicon), 1.5 mg/mL rat tail collagen I (BD Biosciences), 1.5 mg/mL sodium bicarbonate (SigmaAldrich), 25 mmol/L HEPES (Invitrogen), 10% FBS, and 30% complete EGM-2 in endothelial basal medium-2, with an adjusted pH of 7.4. The cellularized suspension was allowed to polymerize at 37 C for 30 minutes in a tissue culture plate and covered with complete EGM-2 for overnight incubation at 37 C in 5% CO 2 . Gels were implanted into the flanks of anesthetized 18-to 20-weekold NOD/SCID mice. The mice were euthanized with CO2 inhalation on day 21, and the gels were removed, preserved in 10% formalin, embedded in paraffin, and evaluated by immunohistochemistry with anti-human CD31 antibodies.
Statistical analyses. Quantitative data are represented as mean 6 standard error of the mean. Comparisons between groups of cells were performed with a paired ttest.
RESULTS
Phenotypic and functional characterization of GSV ECFCs. The primary purpose of this exploratory investigation was to determine whether the adult blood vessel endothelium contained an EPC, specifically an ECFC. We detached expanding colonies with cobblestone morphology at day 3 through 7 of culture amidst a background of nonproliferating endothelial cells with a cloning cylinder. These CFCs were replated and rapidly grew to confluence within 7 days (Fig 1) . GSV ECFCs expressed the endothelial cell surface antigens CD31, CD144, CD105, and KDR and did not express the hematopoietic cell antigen CD45, consistent with the immunophenotype of CB ECFCs (Fig 2, A and B) . Early passage (2-3) GSV ECFCs readily incorporated DiI-Ac-LDL (Fig 2, C) and rapidly formed tube-like structures in Matrigel after 24 hours of incubation (Fig 2, D) , confirming their endothelial lineage. Next, we compared the expression of embryonic stem cell antigens Oct-3/4, Nanog, and SSEA-3 and -4 on CB and GSV ECFCs (Fig 3) . Like CB ECFCs, GSV ECFCs expressed Oct-3/4, Nanog, and SSEA-4 but not SSEA-3.
Proliferative capacity of GSV and CB ECFCs. After establishing that the expanding cobblestone colonies obtained from GSV endothelium possessed the functional and immunocytochemical phenotype of endothelial cells, we next sought to quantify their proliferative capacity using PD and single-cell assays. By assessing the proliferative capacity compared with CB ECFCs, our intent was to assess the relative "stemness" of GSV ECFCs. We found that the average PDT for GSV ECFCs was nearly equivalent to that of CB ECFCs (1.03 6 0.27 vs 1.07 6 0.07, respectively; P ¼ .82 ; Fig 4, A) . After 45 days in culture, GSV ECFCs underwent CPDLs of 35.7 6 1.8 (n ¼ 4) vs CB ECFCs of 47.4 6 3.2 (n ¼ 4; P ¼ .09 ; Fig 4, B) . Using a single-cell clonogenic assay, we found 29.3% 6 0.43% of GSV ECFCs underwent at least one division after 14 days in cell culture vs 32.8% 6 1.3% of CB ECFCs (P ¼ .07, n ¼ 6; Fig 4, C) . Stratification of these matched GSV ECFC and CB ECFC samples into endothelial clusters, low proliferative potential-ECFCs, and HPP-ECFCs revealed a similar distribution of clonogenic potential. In fact, the dividing GSV ECFC populations contained a statistically equivalent number of HPP-ECFCs (74.5% 6 2.9%) as CB ECFCs (69.4% 6 0.7%; P ¼ .34, n ¼ 9 ;  Fig 4, D) . When we further subdivided the HPP groups, we found that, as described in the hematopoietic stem cell lineage, the population of HPP GSV ECFCs that formed large colonies containing >10,000 cells was 30.23% 6 3.5% compared with 43.99% 6 0.70% of CB ECFCs (P ¼ .06, n ¼ 3; Fig 4, E) .
GSV ECFCs form chimeric blood vessels in vivo.
A defining characteristic of stem and progenitor cells is their ability to differentiate into mature functioning cells of the intended lineage in vivo. 29 A previous study showed CB-derived ECFCs developed chimeric functioning blood vessels in a subcutaneous gel implant in immunodeficient mice 10 ; thus, we assessed the vasculogenic capacity of GSV ECFC using the same assay. Intact vessels were identified by positive staining for human CD31. GSV ECFCs formed intact blood vessels after 21 days of implantation in NOD/SCID mice. An important characteristic is the vessels grown became functional murine vessels, as shown by a representative image that contains murine red blood cells flowing through human (CD31 þ ) endothelium (Fig 5) . GSV ECFCs were not as efficient as CB ECFCs in forming microvessels (20.23 6 2.07 vs 43.51 6 3.31; P ¼ .05); however, this emphasizes that GSV ECFCs are capable of forming mature, functioning blood vessels in vivo.
DISCUSSION
In this investigation we have shown that ECFCs from the GSV possess equivalent proliferative and vasculogenic capacity as those isolated from umbilical CB. The prevailing theory of a circulating EPC, or endothelial colony-forming unit, that migrates to, engrafts, and proliferates in areas of vascular injury is disintegrating as evidence accumulates that these cells are derived from the hematopoietic system, differentiate into macrophages, and do not form perfused vessels in vivo. 9 In mouse models of hind limb ischemia, atherogenesis, and tumor angiogenesis, bone marrow-derived circulating EPCs do not incorporate into the growing vasculature or contribute to plaque endothelium. [18] [19] [20] Thus, there appears to be an evolving paradigm shift to the original concept that endothelial cells adjacent to areas of injury or denudation migrate, proliferate, and replace damaged endothelium. The results of our study confirm the presence of such a cell that is capable of endothelial regeneration and thus opens a new focus on the role of ECFCs in vascular homeostasis and disease.
There have been previous reports of resident progenitor cells isolated from blood vessels. Zengin et al 21 described
e EPC localized between the smooth muscle and adventitial layer of human adult vascular wall that formed capillary sprouts ex vivo. Vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia have been described in the human fetal aorta, 22 and CD34 þ CD31 þ pericytes isolated from saphenous vein and adventitia supported angiogenesis through paracrine mechanisms. 23 We have previously characterized ECFCs from the chorionic villi of term human placenta that were highly proliferative and vasculogenic. 24 In this report, with immunohistochemical staining for human CD31, we show that endothelial cells collected from the luminal surface of the GSV give rise to ECFCs that, although not quite as effective as CB ECFCs, are still directly incorporated into functioning blood vessels containing murine red blood cells, providing evidence that GSV ECFCs are capable of functional reconstitution in an in vivo vasculogenic model, a feature that has not been described in the previous reports describing vascular progenitor cells. GSV and CB ECFCs both expressed the embryonic stem cell antigens Oct-4, a transcription factor that is part of a regulatory system that maintains pluripotency and is used as a reprogramming marker for induced pluripotent cells, 25, 26 Nanog, an embryonic stem cell transcription factor critically involved in the maintenance of pluripotency and self-renewal, and SSEA-4 but not SSEA-3. SSEA-3 and -4 are cell surface globoseries glycosphingolipid epitopes that are commonly used as markers for human embryonic stem cells; SSEA-4 remains after embryogenesis, whereas SSEA-3 rapidly disappears when cells start to differentiate. 27 Together, the presence of these markers confirms the progenitor phenotype of GSV ECFC and indicates a role in endothelial maintenance in vivo.
As has been previously reported with progenitor cells, 8 we noticed a slight difference in proliferative capacity between the adult GSV ECFCs and CB ECFCs. This slight difference in proliferation potential becomes more noticeable when looking at the highest proliferative capacities (>10,000 cell colonies) but still remains statistically insignificant. Interestingly, we saw greater proliferative potential in GSV ECFCs than Ingram et al 8 saw in adult peripheral blood ECFCs, suggesting that adult circulating ECFCs are functionally exhausted or otherwise not as robust as vessel wall-derived ECFCs. Although ECFCs will likely never be quite as Great saphenous vein (GSV) endothelial colony-forming cells (ECFCs) exhibit comparable proliferative rates to cord blood (CB) ECFCs. GSV or CB ECFCs were continually passaged for 45 days. Cells were counted during each passage to (A) calculate population doubling times (PDTs) (B) and cumulative populationdoubling levels (CPDLs). ECFCs were labeled with cluster of differentiation (CD)144-phycoerythrin (PE) and seeded at a density of 1 cell/well using a FACSVantage Sorter (BD Biosciences, San Jose, Calif). C, After 14 days, the percentage of ECFCs that divided at least once was determined. D, Wells containing these dividing cells were further divided into endothelial clusters (clusters; 2-50 cells), low proliferative potential colonies (LPP; 50-500 cells), and high proliferative potential colonies (HPP; >500 cells). E, HPP colonies containing >10,000 cells were counted.
vasculogenic as neonatal ECFCs, the advantages of having an autologous, expandable, and still highly vasculogenic population of ECFCs for use in cell therapies cannot be understated.
The current field of progenitor cell therapy for critical limb ischemia is centered on autologous bone marrowderived mononuclear cells and mesenchymal stem cells of autologous and allogeneic origins. [28] [29] [30] The mechanism by which these cells augment perfusion is through paracrine-mediated angiogenesisdthe outgrowth of capillary buds from pre-existing arterioles in response to growth factors and cytokines produced by the transplanted cells. [31] [32] [33] However, in patients with certain vascular pathologies, such as critical limb ischemia, the ability of the nascent vasculature to participate in the process of angiogenesis is either dysfunctional or exhausted. 34, 35 Vasculogenesis, the process of de novo blood vessel formation, presents a more effective approach to improving perfusion in chronically ischemic tissue. 31 GSV ECFCs present a potentially more effective cell source as we have demonstrated the vasculogenic capabilities of these cells in vivo and shown with immunohistochemical staining that ECFCs are incorporated into the vessel. GSV ECFCs may also present an option for promoting re-endothelialization of the arterial lumen after angioplasty or atherectomy. 36 The GSV is routinely harvested as a conduit for bypass procedures in the coronary and peripheral arterial circulation without significant morbidity or disability and represents a readily available source of ECFCs that can be further expanded before transplantation. We used the GSV as a source because of its ready availability and large size; however, other vein sources are also applicable and could potentially be used to obtain autologous ECFCs. Our laboratory has successfully isolated ECFCs from cephalic and basilic vein and from small fragments of GSV harvested for bypass for limb ischemia. This suggests that any accessible vein, even those smaller than the GSV, could be exploited for use as an ECFC source. Consequently, the ECFC source could be tailored to specific patient requirements or vein availability.
CONCLUSIONS
The findings of the present study have several important clinical implications. Firstly, it identifies a progenitor cell population resident in the endothelium of an adult blood vessel containing a hierarchy of proliferative clones capable of functional reconstitution of lineagedependent tissue. Secondly, the data provide a platform to begin investigations into the feasibility of using these cells in autologous cell-based therapies for vascular diseases. Endothelial colony-forming cells (ECFCs), also referred to as "late" EPCs 5 or blood outgrowth endothelial cells, 6 have been isolated from peripheral blood, umbilical cord blood, and other tissues. 7 These cells express endothelial markers including CD31, CD146, CD309, CD144, von Willebrand factor, and endothelial nitric oxide synthase and take up acetylated low-density lipoprotein. 8 They exhibit a profound vascularization capacity in vivo by integrating into the endothelial lining and forming intact vessels containing red blood cells when transplanted into NOD/SCID mice. 9 Differing from early EPCs that originate from hematopoietic lineages, ECFCs do not express hematopoietic (CD45, CD14, CD115) or mesenchymal markers (CD70, smooth muscle actin) 10 and display high proliferative and colony-forming capacity, which promise a quick replication of the cells for clinical application. 8 Accumulating studies suggest that highly proliferative ECFC is an emerging therapeutic option to facilitate endothelial regeneration for a variety of cardiovascular diseases. In this study, Green et al successfully isolated a hierarchy of progenitor cells from the endothelium of human great saphenous vein. These cells express endothelial markers but not hematopoietic markers and display high proliferative capacity and in vivo vascularization potency comparable to ECFCs isolated from cord blood. This innovative 
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